OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Batra-Sharma on Conducting a Clinicopathologic Investigation Into Metaplastic Breast Cancer

August 9th 2023

Hemali Batra-Sharma, MD, discusses a single-institution, retrospective clinicopathologic analysis of patients with metaplastic breast cancer, findings from which were presented at the 2023 ASCO Annual Meeting.

Dr Reckamp on the Landscape of Current and Emerging ADCs in NSCLC

August 9th 2023

Karen L. Reckamp, MD, MS, discusses current and emerging antibody-drug conjugates in lung cancer in addition to highlighting the development of patritumab deruxtecan and telisotuzumab vedotin.

Dr Jänne on the FLAURA2 and MARIPOSA Trials of Single-Agent Osimertinib in EGFR-Mutant NSCLC

August 9th 2023

Pasi A. Jänne, MD, PhD, discusses key trials evaluating the efficacy of single-agent osimertinib in patients with metastatic EGFR-mutated non–small cell lung cancer.

Dr Massarelli on Effectively Treating Patients During the United States Chemotherapy Shortage

August 8th 2023

Erminia Massarelli MD, PhD, MS, discusses strategies created by City of Hope to effectively navigate the treatment of patients with lung cancer during the platinum chemotherapy shortage in the United States.

Dr Patel on the Background of the KarMMa-3 Trial in Relapsed/Refractory Multiple Myeloma

August 8th 2023

Krina K. Patel, MD, MSc, discusses the background of the phase 3 KarMMa-3 trial, which investigated idecabtagene vicleucel in patients with high-risk, relapsed/refractory multiple myeloma.

Dr Danish on the Potential for Treatment with SCINTIX Radiation Technology in Lung and Bone Cancers

August 8th 2023

Adnan F. Danish, MD, discusses the potential for SCINTIX radiation technology to open new treatment opportunities for patients with cancer, including those with lung and bone cancers, whose disease has metastasized to more than 5 sites.

Dr Vaishampayan on Patient Considerations When Choosing Between FDA-Approved Therapies in nmCRPC

August 8th 2023

Ulka Nitin Vaishampayan, MBBS, discusses patient factors to consider when choosing between apalutamide, enzalutamide, and darolutamide for the treatment of patients with non-metastatic castration resistant prostate cancer.

Dr Santos on Steps Taken to Address the Chemotherapy Shortage in the United States

August 8th 2023

Edgardo Santos MD, FACP, FCCP, discusses how cancer centers across the United States are minimizing the negative effects of the ongoing carboplatin and cisplatin shortage, and details potential next steps that should be taken to prevent drug shortages like this from occurring in the future.

Dr Peters on the Steps Being Taken to Address Chemotherapy Shortages in Cancer Care

August 7th 2023

Solange Peters, MD, PhD, discusses steps being taken to address the ongoing platinum chemotherapy shortage in the United States for patients with cancer.

Dr Wakelee on Unmet Needs in Cancer Care Because of the United States Chemotherapy Shortage

August 7th 2023

Heather Wakelee, MD, FASCO, discusses unmet needs in cancer care stemming from the ongoing platinum chemotherapy shortage in the United States, highlighting the need for newer, better drugs to help treat patients.

Dr Kim on the Effects of Drug Shortages in Cancer Care and How to Mitigate Them

August 7th 2023

Edward S. Kim, MD, MBA, discusses drug shortages in cancer care, detailing how City of Hope has continued to establish efforts to mitigate the effects of these shortages.

Dr Lin on the Selection of Systemic Therapy in HER2+ Breast Cancer With Brain Metastases

August 7th 2023

Nancy U. Lin, MD, discusses selecting between systemic vs local therapy for patients with HER2-positive breast cancer displaying central nervous system metastases.

Dr Li on the Rationale for Evaluating CG0070 Plus Pembrolizumab in BCG-Unresponsive NMIBC

August 7th 2023

Roger Li, MD, expands on the mechanism of action for the combination of CG0070 and pembrolizumab, and discusses the rationale for investigating the regimen's synergy in patients with non–muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guérin.

Dr Doroshow on RET Inhibitors in RET Fusion+ NSCLC

August 4th 2023

Deborah B. Doroshow, MD, PhD, discusses the similarities and differences between the efficacy and safety profiles of pralsetinib and selpercatinib in patients with non–small cell lung cancer harboring RET fusions.

Dr Massarelli on NTRK Inhibitors in NTRK Fusion+ NSCLC

August 4th 2023

Erminia Massarelli MD, PhD, MS, discusses efficacy and safety data with the NTRK inhibitors larotrectinib and entrectinib in patients with non–small cell lung cancer harboring NTRK fusions.

Dr Abdou on Treatment Sequencing With CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

August 4th 2023

Yara Abdou, MD, discusses treatment sequencing with CDK4/6 inhibitors across all lines of therapy in patients with hormone receptor–positive, HER2-negative breast cancer.

Dr Bloomer on the Rationale for the ColoCare Study in Newly Diagnosed CRC

August 4th 2023

Amanda Bloomer, PhD, discusses the rationale for launching the ColoCare study, an investigation into the health-related quality of life outcomes of younger vs older adult patients with newly diagnosed colorectal cancer.

Dr Frank on Sequencing Questions With CAR22 in Relapsed/Refractory LBCL

August 4th 2023

Matthew J. Frank, MD, PhD, discusses remaining questions regarding treatment sequencing following preliminary results from a phase 1 trial of a CD22-directed CAR-T therapy in relapsed/refractory large B-cell lymphoma.

Dr Wakelee on Key Trials With Perioperative Immunotherapy in Early-Stage NSCLC

August 4th 2023

Heather Wakelee, MD, FASCO, discusses the clinical significance of updated data from several key trials evaluating perioperative immunotherapy in early-stage non–small cell lung cancer.

Dr Kwendakwema on the Effects of Financial Toxicity on Treatment Costs in Patients With Cancer

August 3rd 2023

Natasha Kwendakwema, MD, discusses findings from a study on the effects of adverse financial events on treatment costs at the end of life and health care utilization in patients with cancer.